WO2023046605 - ENHANCED SYSTEM FOR TREATING A BIOTECHNOLOGICAL FLUID USING AN ADAPTIVE SOFTWARE

National phase entry:
Publication Number WO/2023/046605
Publication Date 30.03.2023
International Application No. PCT/EP2022/075874
International Filing Date 19.09.2022
Title **
[English] ENHANCED SYSTEM FOR TREATING A BIOTECHNOLOGICAL FLUID USING AN ADAPTIVE SOFTWARE
[French] SYSTÈME AMÉLIORÉ DE TRAITEMENT D'UN FLUIDE BIOTECHNOLOGIQUE À L'AIDE D'UN LOGICIEL ADAPTATIF
Applicants **
MERCK PATENT GMBH Frankfurter Strasse 250 64293 Darmstadt, DE
Inventors
EBERHARD, Philippe c/o Millipore S.A.S. 39, Route Industrielle de la Hardt 67120 MOLSHEIM, FR
REINBIGLER, Rene c/o Millipore S.A.S. 39, Route Industrielle de la Hardt 67120 MOLSHEIM, FR
DUBRET, Denis c/o Millipore S.A.S. 39, Route Industrielle de la Hardt 67120 MOLSHEIM, FR
MILLER, Steven c/o Millipore S.A.S. 39, Route Industrielle de la Hardt 67120 Molsheim, FR
Priority Data
21306311.8   22.09.2021   EP
front page image
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
*
International Searching Authority
*
Applicant's Legal Status
*
*
*
*
*
Entry into National Phase under
*
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing1348
EPO Filing, Examination5345
Japan Filing593
South Korea Filing575
USA Filing, Examination2710
MasterCard Visa

Total: 10571

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Abstract[English] The present application relates to biotechnological fluid treating, such as biopharmaceutical liquids in order to obtain products such as monoclonal antibodies, vaccines or recombinant proteins, and particularly to a system for treating a biotechnical fluid, having a bioprocess machine and at least one bioprocess machine helper, configured to connect to each other and each comprising a controller, in turn comprising a machine-to-machine communication tool configured for connecting to a network, wherein parts of the bioprocess machine helper are simulated and used to enhance the behaviour of the disclosed system.[French] La présente invention concerne le traitement biotechnologique de fluides, tels que des liquides biopharmaceutiques afin d'obtenir des produits tels que des anticorps monoclonaux, des vaccins ou des protéines recombinées, et en particulier un système de traitement d'un fluide biotechnologique, ayant une machine de bioprocédé et au moins un auxiliaire de machine de bioprocédé, configurés pour se connecter l'un à l'autre et comprenant chacun un dispositif de commande, comprenant à son tour un outil de communication de machine à machine configuré pour se connecter à un réseau, des parties de l'auxiliaire de machine de bioprocédé étant simulées et utilisées pour améliorer le comportement du système décrit.
An unhandled error has occurred. Reload 🗙